S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Ibere Pharmaceuticals Stock Forecast, Price & News

0.00 (0.00%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
83,974 shs
Average Volume
11,323 shs
Market Capitalization
$168.02 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive IBER News and Ratings via Email

Sign-up to receive the latest news and ratings for Ibere Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Ibere Pharmaceuticals

Ibere Pharmaceuticals focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in Philadelphia, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Holding & other investment offices
Year Founded

Sales & Book Value

Annual Sales
Book Value
($0.65) per share


Pretax Margin




Free Float
Market Cap
$168.02 million
Not Optionable

Company Calendar

Fiscal Year End


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1385th out of 1,391 stocks

Holding & Other Investment Offices Industry

453rd out of 519 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Ibere Pharmaceuticals (NYSE:IBER) Frequently Asked Questions

Are investors shorting Ibere Pharmaceuticals?

Ibere Pharmaceuticals saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 2,600 shares, a decline of 25.7% from the October 31st total of 3,500 shares. Based on an average daily volume of 6,600 shares, the short-interest ratio is currently 0.4 days.
View Ibere Pharmaceuticals' Short Interest

Who are Ibere Pharmaceuticals' key executives?

Ibere Pharmaceuticals' management team includes the following people:
  • Mr. Osagie O. Imasogie, Chairman & CEO (Age 59)
  • Ms. Lisa M. Gray, CFO, EVP & Director (Age 56)
  • Mr. Zoltan Kerekes J.D., COO, EVP & Director (Age 55)

What is Ibere Pharmaceuticals' stock symbol?

Ibere Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "IBER."

Who are Ibere Pharmaceuticals' major shareholders?

Ibere Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Hudson Bay Capital Management LP (3.58%), Goldman Sachs Group Inc. (0.32%), Dark Forest Capital Management LP (0.26%) and Robinson Capital Management LLC (0.10%).

Which institutional investors are selling Ibere Pharmaceuticals stock?

IBER stock was sold by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP.

Which institutional investors are buying Ibere Pharmaceuticals stock?

IBER stock was purchased by a variety of institutional investors in the last quarter, including Dark Forest Capital Management LP, Robinson Capital Management LLC, and Goldman Sachs Group Inc..

How do I buy shares of Ibere Pharmaceuticals?

Shares of IBER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ibere Pharmaceuticals' stock price today?

One share of IBER stock can currently be purchased for approximately $9.74.

How much money does Ibere Pharmaceuticals make?

Ibere Pharmaceuticals has a market capitalization of $168.02 million.

How many employees does Ibere Pharmaceuticals have?

Ibere Pharmaceuticals employs 3 workers across the globe.

What is Ibere Pharmaceuticals' official website?

The official website for Ibere Pharmaceuticals is www.iberepharma.com.

Where are Ibere Pharmaceuticals' headquarters?

Ibere Pharmaceuticals is headquartered at 2005 MARKET STREET SUITE 2030, PHILADELPHIA PA, 19103.

How can I contact Ibere Pharmaceuticals?

Ibere Pharmaceuticals' mailing address is 2005 MARKET STREET SUITE 2030, PHILADELPHIA PA, 19103. The company can be reached via phone at 267-765-3222.

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.